Literature DB >> 15255797

Bioavailabilities of rectal and oral methadone in healthy subjects.

Ola Dale1, Pamela Sheffels, Evan D Kharasch.   

Abstract

AIMS: Rectal administration of methadone may be an alternative to intravenous and oral dosing in cancer pain, but the bioavailability of the rectal route is not known. The aim of this study was to compare the absolute rectal bioavailability of methadone with its oral bioavailability in healthy humans.
METHODS: Seven healthy subjects (six males, one female, aged 20-39 years) received 10 mg d(5)-methadone-HCl rectally (5 ml in 20% glycofurol) together with either d(0)-methadone intravenously (5 mg) or orally (10 mg) on two separate occasions. Blood samples for the LC-MS analyses of methadone and it's metabolite EDDP were drawn for up to 96 h. Noninvasive infrared pupillometry was performed at the same time as blood sampling.
RESULTS: The mean absolute rectal bioavailability of methadone was 0.76 (0.7, 0.81), compared to 0.86 (0.75, 0.97) for oral administration (mean (95% CI)). Rectal absorption of methadone was more rapid than after oral dosing with Tmax values of 1.4 (0.9, 1.8) vs. 2.8 (1.6, 4.0) h. The extent of formation of the metabolite EDDP did not differ between routes of administration. Single doses of methadone had a duration of action of at least 10 h and were well tolerated.
CONCLUSIONS: Rectal administration of methadone results in rapid absorption, a high bioavailability and long duration of action. No evidence of presystemic elimination was seen. Rectal methadone has characteristics that make it a potential alternative to intravenous and oral administration, particularly in cancer pain and palliative care.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15255797      PMCID: PMC1884589          DOI: 10.1111/j.1365-2125.2004.02116.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  31 in total

Review 1.  Symptom control in cancer patients: the clinical pharmacology and therapeutic role of suppositories and rectal suspensions.

Authors:  Mellar P Davis; Declan Walsh; Susan B LeGrand; Michael Naughton
Journal:  Support Care Cancer       Date:  2001-11-09       Impact factor: 3.603

Review 2.  Review of the rectal use of opioids.

Authors:  L Cole; C D Hanning
Journal:  J Pain Symptom Manage       Date:  1990-04       Impact factor: 3.612

3.  Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain: clinical and economic considerations.

Authors:  S Watanabe; M Belzile; N Kuehn; J Hanson; E Bruera
Journal:  Cancer Treat Rev       Date:  1996-01       Impact factor: 12.111

Review 4.  An update on the clinical use of methadone for cancer pain.

Authors:  C Ripamonti; E Zecca; E Bruera
Journal:  Pain       Date:  1997-04       Impact factor: 6.961

5.  Use of methadone in a highly tolerant patient receiving parenteral hydromorphone.

Authors:  Z Thomas; E Bruera
Journal:  J Pain Symptom Manage       Date:  1995-05       Impact factor: 3.612

Review 6.  The use of methadone for cancer pain.

Authors:  Carla Ripamonti; Mauro Bianchi
Journal:  Hematol Oncol Clin North Am       Date:  2002-06       Impact factor: 3.722

Review 7.  Nasal administration of opioids for pain management in adults.

Authors:  O Dale; R Hjortkjaer; E D Kharasch
Journal:  Acta Anaesthesiol Scand       Date:  2002-08       Impact factor: 2.105

8.  Preliminary study on the absorption profile after rectal and oral administration of methadone in human volunteers.

Authors:  F Moolenaar; G Fiets; J Visser; D K Meijer
Journal:  Pharm Weekbl Sci       Date:  1984-12-14

9.  Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?

Authors:  C Ripamonti; L Groff; C Brunelli; D Polastri; A Stavrakis; F De Conno
Journal:  J Clin Oncol       Date:  1998-10       Impact factor: 44.544

10.  Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home.

Authors:  S Mercadante; A Casuccio; A Agnello; R Serretta; L Calderone; L Barresi
Journal:  J Clin Oncol       Date:  1998-11       Impact factor: 44.544

View more
  13 in total

Review 1.  Methadone for treatment of cancer pain.

Authors:  John Bryson; Anoo Tamber; Dori Seccareccia; Camilla Zimmermann
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

2.  Methadone dosing strategies in preterm neonates can be simplified.

Authors:  Tamara van Donge; Samira Samiee-Zafarghandy; Marc Pfister; Gilbert Koch; Majid Kalani; Arash Bordbar; John van den Anker
Journal:  Br J Clin Pharmacol       Date:  2019-04-10       Impact factor: 4.335

3.  Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19.

Authors:  Alice Ban Ke; Srikanth C Nallani; Ping Zhao; Amin Rostami-Hodjegan; Jashvant D Unadkat
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

4.  Effect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine-naloxone in subjects receiving stable addiction management therapy.

Authors:  David Joseph; Michael J Schobelock; Robert R Riesenberg; Bradley D Vince; Lynn R Webster; Abidemi Adeniji; Mabrouk Elgadi; Fenglei Huang
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

5.  Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals.

Authors:  Sandra D Comer; Maria A Sullivan; Ellen A Walker
Journal:  J Pharmacol Exp Ther       Date:  2005-09-06       Impact factor: 4.030

6.  Effect of rilpivirine on the pharmacokinetics of methadone in HIV-Infected Chinese patients.

Authors:  Suyun Lei; Lizhu Hong; Cuixian Yang; Shuang Zhang; Yanyun Zhang; Shizhen Huang; Ronghui Xie; Xia Li; Qing Ma; Huiqin Li
Journal:  Expert Rev Clin Pharmacol       Date:  2019-05-15       Impact factor: 5.045

7.  Prefrontal cortex response to drug cues, craving, and current depressive symptoms are associated with treatment outcomes in methadone-maintained patients.

Authors:  Andrew S Huhn; Mary M Sweeney; Robert K Brooner; Michael S Kidorf; D Andrew Tompkins; Hasan Ayaz; Kelly E Dunn
Journal:  Neuropsychopharmacology       Date:  2018-10-30       Impact factor: 7.853

8.  The pharmacokinetics of methadone and its metabolites in neonates, infants, and children.

Authors:  Robert M Ward; David R Drover; Gregory B Hammer; Christopher J Stemland; Steve Kern; Martin Tristani-Firouzi; Ralph A Lugo; Kristin Satterfield; Brian J Anderson
Journal:  Paediatr Anaesth       Date:  2014-03-26       Impact factor: 2.556

9.  Increased neural activity in the right dorsolateral prefrontal cortex during a risky decision-making task is associated with cocaine use in methadone-maintained patients.

Authors:  Andrew S Huhn; Robert K Brooner; Mary M Sweeney; Sarah W Yip; Hasan Ayaz; Kelly E Dunn
Journal:  Drug Alcohol Depend       Date:  2019-10-20       Impact factor: 4.492

10.  The association of prefrontal cortex response during a natural reward cue-reactivity paradigm, anhedonia, and demoralization in persons maintained on methadone.

Authors:  Andrew S Huhn; Robert K Brooner; Mary M Sweeney; Denis Antoine; Alexis S Hammond; Hasan Ayaz; Kelly E Dunn
Journal:  Addict Behav       Date:  2020-09-28       Impact factor: 3.913

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.